DalsnaFinance

Taysha Gene Therapies Inc $TSHA

Health Care

Russell 2000 Texas
Create a scorecard
$4.01
-0.12 (-2.79%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Loading chart…

Taysha Gene Therapies Inc (TSHA) is trading down at $4.01 (-2.79%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: September 24, 2020 · $20.00 offering · NASDAQ · View IPO details →

Taysha Gene Therapies Inc revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)
$15.5M−$79.5M−$174.5MFY2020 net income: −$60.0M'20FY2021 net income: −$174.5M'21FY2022 revenue: $2.50MFY2022 net income: −$166.0M · Net margin −6635.3%'22FY2023 revenue: $15.5MFY2023 net income: −$111.6M · Net margin −722.1%'23FY2024 revenue: $8.33MFY2024 net income: −$89.3M · Net margin −1071.6%'24FY2025 revenue: $9.77MFY2025 net income: −$109.0M · Net margin −1115.3%'25−100%−75%−50%−25%0%FY2022 net margin: −6635.3% (off the scale, which stops at −100.0%)FY2023 net margin: −722.1% (off the scale, which stops at −100.0%)FY2024 net margin: −1071.6% (off the scale, which stops at −100.0%)FY2025 net margin: −1115.3% (off the scale, which stops at −100.0%)
Taysha Gene Therapies Inc annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue——$2.50M$15.5M$8.33M$9.77M
Growth (year over year)———+517.5%−46.1%+17.3%
Operating income−$43.0M−$173.3M−$162.4M−$72.4M−$91.5M−$110.5M
Operating margin——−6492.7%−468.8%−1097.6%−1130.6%
Net income−$60.0M−$174.5M−$166.0M−$111.6M−$89.3M−$109.0M
Net margin——−6635.3%−722.1%−1071.6%−1115.3%
EPS (diluted)−$3.40−$4.64−$3.78−$0.96−$0.36−$0.34
Balance sheet
Cash and equivalents$251.3M$149.1M$87.9M$143.9M$139.0M$319.8M
Total assets$258.9M$214.0M$126.3M$172.7M$160.4M$343.3M
Total liabilities$7.58M$118.6M$125.3M$97.8M$88.8M$96.4M
Long-term debt—$37.2M$38.0M$40.5M$43.9M$50.1M
Shareholders' equity$251.3M$95.4M$949.0K$74.9M$71.5M$246.9M
Cash flow
Operating cash flow−$30.7M−$117.0M−$88.4M−$73.0M−$81.2M−$93.1M
Capital expenditure$82.0K$15.3M$20.6M$3.87M$374.0K$738.0K
Free cash flow−$30.8M−$132.3M−$109.0M−$76.9M−$81.6M−$93.8M

From Taysha Gene Therapies Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Taysha Gene Therapies Inc

Headquarters
Dallas, Texas From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →